Cyprotex
Mark Wenlock is a Group Leader at Cyprotex, overseeing the expansion and diversification of Physical Chemistry services. With a background in in silico ADMET research at AstraZeneca, Mark has extensive experience in predictive sciences, physical organic chemistry, and drug design. As a Director at InSilicoLynx, Mark focused on developing software for Medicinal Chemistry access to in-vivo exposure parameter estimates. With a PhD in Organic Chemistry from Cardiff University, Mark is a skilled scientist with expertise in aqueous solubility, hydrophobicity, pKa, and plasma protein binding.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology